0001831492-20-000001.txt : 20201112 0001831492-20-000001.hdr.sgml : 20201112 20201110192930 ACCESSION NUMBER: 0001831492-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20201112 DATE AS OF CHANGE: 20201110 EFFECTIVENESS DATE: 20201112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biocure Technology Inc. CENTRAL INDEX KEY: 0001831492 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-380257 FILM NUMBER: 201302600 BUSINESS ADDRESS: STREET 1: 300 - 1055 WEST HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6E 2E9 BUSINESS PHONE: 604-609-7149 MAIL ADDRESS: STREET 1: 300 - 1055 WEST HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6E 2E9 D 1 primary_doc.xml X0708 D LIVE 0001831492 Biocure Technology Inc. 300 - 1055 WEST HASTINGS STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6E 2E9 604-609-7149 BRITISH COLUMBIA, CANADA Gravis Energy Corp. Sukari Ventures Corp. None Corporation true Sang Mok Lee 300 - 1055 West Hastings Street Vancouver A1 BRITISH COLUMBIA, CANADA V6E 2E9 Executive Officer Director Konstantin Konstantin Lichtenwald 300 - 1055 West Hastings Street Vancouver A1 BRITISH COLUMBIA, CANADA V6E 2E9 Executive Officer Director Sang Goo (Collin) Kim 300 - 1055 West Hastings Street Vancouver A1 BRITISH COLUMBIA, CANADA V6E 2E9 Director Hans Frykman 300 - 1055 West Hastings Street Vancouver A1 BRITISH COLUMBIA, CANADA V6E 2E9 Director Danny Joh 300 - 1055 West Hastings Street Vancouver A1 BRITISH COLUMBIA, CANADA V6E 2E9 Director Pharmaceuticals No Revenues 06b false 2020-10-14 true true true true true Units, each comprised of one common share and one common share purchase warrant, with each warrant having a CAD$0.21 exercise price and a 2-year term. false 0 26639 10656 15983 US dollars have been converted from Canadian dollars using the 0.7611 Bank of Canada daily exchange rate on 10-14-20. Total Remaining to be Sold represents the aggregate exercise price of warrants sold in the offering in the United States. false 1 0 0 0 true Proceeds of the offering may be used for general working capital purposes and may thus be used for payments to officers and directors in the ordinary course but have not been specifically earmarked for such payments. false Biocure Technology Inc. /s/ Konstantin Lichtenwald Konstantin Lichtenwald Chief Financial Officer 2020-11-10